ES2742224T3 - Anticuerpos biespecíficos anti-WT1/HLA - Google Patents

Anticuerpos biespecíficos anti-WT1/HLA Download PDF

Info

Publication number
ES2742224T3
ES2742224T3 ES14803300T ES14803300T ES2742224T3 ES 2742224 T3 ES2742224 T3 ES 2742224T3 ES 14803300 T ES14803300 T ES 14803300T ES 14803300 T ES14803300 T ES 14803300T ES 2742224 T3 ES2742224 T3 ES 2742224T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14803300T
Other languages
English (en)
Spanish (es)
Inventor
David Scheinberg
Jingyi Xiang
Tao Dao
Su Yan
Cheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Original Assignee
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc filed Critical Memorial Sloan Kettering Cancer Center
Application granted granted Critical
Publication of ES2742224T3 publication Critical patent/ES2742224T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES14803300T 2013-11-07 2014-11-07 Anticuerpos biespecíficos anti-WT1/HLA Active ES2742224T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361901310P 2013-11-07 2013-11-07
US201462037875P 2014-08-15 2014-08-15
PCT/US2014/064621 WO2015070061A1 (en) 2013-11-07 2014-11-07 Anti-wt1/hla bi-specific antibody

Publications (1)

Publication Number Publication Date
ES2742224T3 true ES2742224T3 (es) 2020-02-13

Family

ID=51987482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14803300T Active ES2742224T3 (es) 2013-11-07 2014-11-07 Anticuerpos biespecíficos anti-WT1/HLA

Country Status (5)

Country Link
EP (1) EP3066130B1 (enExample)
JP (1) JP6553069B2 (enExample)
CN (1) CN106414500B (enExample)
ES (1) ES2742224T3 (enExample)
WO (1) WO2015070061A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2017060201A1 (en) * 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
WO2019006464A1 (en) 2017-06-30 2019-01-03 Memorial Sloan Kettering Cancer Center COMPOSITIONS AND METHODS OF ADOPTIVE CELLULAR THERAPY AGAINST CANCER
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
PE20201149A1 (es) 2017-12-21 2020-10-26 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112041432A (zh) 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
CN112512538A (zh) * 2018-05-18 2021-03-16 国家儿童医疗中心 改进的靶向t细胞疗法
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP4126044A4 (en) * 2020-04-02 2024-09-04 The Board Of Regents Of The University Of Texas System CD5L-BINDING ANTIBODIES AND USES THEREOF
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
IL300543A (en) * 2020-09-24 2023-04-01 Hoffmann La Roche Prevention or reduction of adverse effects associated with a bispecific T-cell antibody
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
JP2025513714A (ja) * 2022-03-22 2025-04-30 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃｄ３に特異的な脱免疫抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
ES2785081T3 (es) * 2011-04-01 2020-10-05 Memorial Sloan Kettering Cancer Center Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2

Also Published As

Publication number Publication date
JP2017500057A (ja) 2017-01-05
CN106414500A (zh) 2017-02-15
WO2015070061A1 (en) 2015-05-14
EP3066130B1 (en) 2019-05-15
JP6553069B2 (ja) 2019-07-31
CN106414500B (zh) 2020-04-10
EP3066130A1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
JP6553069B2 (ja) 抗ｗｔ１／ｈｌａ二重特異性抗体
ES2809455T3 (es) Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
ES2914177T3 (es) Anticuerpos anti-OX40 humanizados y usos de los mismos
US10239952B2 (en) Anti-WT1/HLA bi-specific antibody
ES2955074T3 (es) Proteínas que se unen a HER2, NKG2D Y CD16
US12491244B2 (en) Pharmaceutical combinations for treating tumor comprising anti-CD19 antibody and natural killer cell
ES2935120T3 (es) Anticuerpos anti-PSMA, moléculas de unión a antígeno biespecíficas que se unen a PSMA y a CD3, y sus usos
ES2845924T3 (es) Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
US11091546B2 (en) Optimized PNE-based chimeric receptor T cell switches and uses thereof
ES2948807T3 (es) Anticuerpos anti CD3, moléculas de unión a antígeno biespecíficas que se unen a CD3 y a CD20 y usos de los mismos
ES2978993T3 (es) Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
ES2784131T3 (es) Polipéptidos de unión beta del receptor PDGF
ES2901133T3 (es) Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos
KR20210013160A (ko) 다중-특이적 결합 단백질 및 그에 대한 개선
ES2717308T3 (es) Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
US10934331B2 (en) Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells
CN109843325A (zh) Cd3结合抗体
US20250129147A1 (en) Epo receptor agonists and antagonists
ES2800674T3 (es) Polipéptidos biespecíficos de unión a antígeno
AU2014346648A1 (en) Fc-enhanced anti-WT1/HLA antibody
KR20220150274A (ko) Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
EP4545562A1 (en) Fusion protein comprising anti-cd73 antibody and il-2, and use thereof
HK1227903A1 (en) Anti-wt1/hla bi-specific antibody
HK1227903B (en) Anti-wt1/hla bi-specific antibody
US20240084014A1 (en) Multispecific binding compounds that bind to pd-l1